Single User License
INR 136220
Site License
INR 272440
Corporate User License
INR 408660

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Helicobacter Pylori Infections-Pipeline Review, H2 2015

Helicobacter Pylori Infections-Pipeline Review, H2 2015


  Request for Sample Report

Executive Summary

Helicobacter Pylori Infections-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Helicobacter Pylori Infections-Pipeline Review, H2 2015', provides an overview of the Helicobacter Pylori Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Helicobacter Pylori Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Helicobacter Pylori Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Helicobacter Pylori Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Helicobacter Pylori Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Helicobacter Pylori Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Helicobacter Pylori Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Helicobacter Pylori Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Helicobacter Pylori Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Helicobacter Pylori Infections Overview 7

Therapeutics Development 8

Pipeline Products for Helicobacter Pylori Infections-Overview 8

Pipeline Products for Helicobacter Pylori Infections-Comparative Analysis 9

Helicobacter Pylori Infections-Therapeutics under Development by Companies 10

Helicobacter Pylori Infections-Therapeutics under Investigation by Universities/Institutes 11

Helicobacter Pylori Infections-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Unknown Stage Products 15

Helicobacter Pylori Infections-Products under Development by Companies 16

Helicobacter Pylori Infections-Products under Investigation by Universities/Institutes 17

Helicobacter Pylori Infections-Companies Involved in Therapeutics Development 18

Daewoong Pharmaceutical Co., Ltd. 18

EpiVax, Inc. 19

ImevaX GmbH 20

ImmunoBiology Limited 21

RedHill Biopharma Ltd. 22

Sequella, Inc. 23

Shanghai Zerun Biotechnology Co., Ltd. 24

Sigmoid Pharma Limited 25

Helicobacter Pylori Infections-Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Combination Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 33

Drug Profiles 35

(rifabutin + amoxicillin sodium + omeprazole sodium)-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

DWJ-1325-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

FROST-900-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Helicobacter pylori [Hel-305] (multivalent) vaccine-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

helicobacter pylori vaccine-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

helicobacter pylori vaccine-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

helicobacter pylori vaccine-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

helicobacter pylori vaccine-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

HPi-1-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

IMX-101-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Small Molecules for Helicobacter Pylori Infections-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Small Molecules to Inhibit DNA Synthesis for Infectious Diseases-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

SQ-109-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Helicobacter Pylori Infections-Recent Pipeline Updates 53

Helicobacter Pylori Infections-Dormant Projects 57

Helicobacter Pylori Infections-Product Development Milestones 59

Featured News & Press Releases 59

Jun 15, 2015: RedHill Biopharma Successfully Meets Primary Endpoint in Phase III Study of RHB-105 for H. pylori Infection 59

Jun 15, 2015: RedHill Biopharma to Host Conference Call to Review Positive Phase III Top-Line Results with RHB-105 for H. pylori Infection 60

Jun 08, 2015: RedHill Biopharma Completes Treatment of Last Patient with RHB-105 in Phase III Study 60

Jun 03, 2015: RedHill Biopharma Provides Update on Development Pipeline and Expected Timing for RHB-105 Phase III Top-Line Results 61

May 07, 2015: RedHill Biopharma to Host Investor Webcast Forum Following Completion of RHB-105 Dosing in Phase III Study 63

Apr 27, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in a Phase III Study of RHB-105 for H. pylori Infection 64

Apr 16, 2015: RedHill Biopharma Receives Notice of Allowance for Additional U.S. Patent for RHB-105 H. pylori Bacterial Infection Treatment 65

Nov 10, 2014: FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase 3 H. Pylori Drug RHB-105 66

Aug 27, 2014: RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA 67

Dec 23, 2013: RedHill Biopharma Reports Positive PK Results in Support of Ongoing RHB-105 Phase III H. pylori Study 69

Appendix 70

Methodology 70

Coverage 70

Secondary Research 70

Primary Research 70

Expert Panel Validation 70

Contact Us 70

Disclaimer 71

List of Tables

Number of Products under Development for Helicobacter Pylori Infections, H2 2015 8

Number of Products under Development for Helicobacter Pylori Infections-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Number of Products under Investigation by Universities/Institutes, H2 2015 11

Comparative Analysis by Late Stage Development, H2 2015 12

Comparative Analysis by Clinical Stage Development, H2 2015 13

Comparative Analysis by Early Stage Development, H2 2015 14

Comparative Analysis by Unknown Stage Development, H2 2015 15

Products under Development by Companies, H2 2015 16

Products under Investigation by Universities/Institutes, H2 2015 17

Helicobacter Pylori Infections-Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015 18

Helicobacter Pylori Infections-Pipeline by EpiVax, Inc., H2 2015 19

Helicobacter Pylori Infections-Pipeline by ImevaX GmbH, H2 2015 20

Helicobacter Pylori Infections-Pipeline by ImmunoBiology Limited, H2 2015 21

Helicobacter Pylori Infections-Pipeline by RedHill Biopharma Ltd., H2 2015 22

Helicobacter Pylori Infections-Pipeline by Sequella, Inc., H2 2015 23

Helicobacter Pylori Infections-Pipeline by Shanghai Zerun Biotechnology Co., Ltd., H2 2015 24

Helicobacter Pylori Infections-Pipeline by Sigmoid Pharma Limited, H2 2015 25

Assessment by Monotherapy Products, H2 2015 26

Assessment by Combination Products, H2 2015 27

Number of Products by Stage and Target, H2 2015 29

Number of Products by Stage and Mechanism of Action, H2 2015 31

Number of Products by Stage and Route of Administration, H2 2015 32

Number of Products by Stage and Molecule Type, H2 2015 34

Helicobacter Pylori Infections Therapeutics-Recent Pipeline Updates, H2 2015 53

Helicobacter Pylori Infections-Dormant Projects, H2 2015 57

Helicobacter Pylori Infections-Dormant Projects (Contd..1), H2 2015 58

List of Figures

Number of Products under Development for Helicobacter Pylori Infections, H2 2015 8

Number of Products under Development for Helicobacter Pylori Infections-Comparative Analysis, H2 2015 9

Number of Products under Development by Companies, H2 2015 10

Comparative Analysis by Early Stage Products, H2 2015 14

Assessment by Monotherapy Products, H2 2015 26

Number of Products by Top 10 Targets, H2 2015 28

Number of Products by Stage and Top 10 Targets, H2 2015 28

Number of Products by Top 10 Mechanism of Actions, H2 2015 30

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 30

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 32

Number of Products by Top 10 Molecule Types, H2 2015 33

Number of Products by Stage and Top 10 Molecule Types, H2 2015 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Daewoong Pharmaceutical Co., Ltd.

EpiVax, Inc.

ImevaX GmbH

ImmunoBiology Limited

RedHill Biopharma Ltd.

Sequella, Inc.

Shanghai Zerun Biotechnology Co., Ltd.

Sigmoid Pharma Limited

Helicobacter Pylori Infections Therapeutic Products under Development, Key Players in Helicobacter Pylori Infections Therapeutics, Helicobacter Pylori Infections Pipeline Overview, Helicobacter Pylori Infections Pipeline, Helicobacter Pylori Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com